FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* O'NEIL PATRICK R.						2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [IONS]								eck all applic Directo	onship of Reporting Person all applicable) Director Officer (give title			n(s) to Issuer 10% Owner Other (specify	
(Last) (First) (Middle) C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT						3. Date of Earliest Transaction (Month/Day/Year) 01/15/2019								below)					
(Street) CARLSBAD CA 92010 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	e) X Form fi Form fi	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Ta	ble I - Nor	n-Deriv	/ativ	e Se	curitie	s Aca	uired.	Dis	nosed of	or Ber	eficiall	v Owned					
1. Title of Security (Instr. 3) 2. Transa Date			action Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amour Securitie Beneficia Owned F	s illy ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price		eported ansaction(s) istr. 3 and 4)		((Instr. 4)		
Common Stock 01/15/				/2019		01/15/	/2019	M ⁽¹⁾	\top	7,823(1)	1) A	\$0	22,	341	D				
Common Stock 01/15/					5/2019		01/15/2019		F ⁽²⁾		2,734 ⁽²⁾) D	\$58.2	6 19,	607]	D		
			Table II -					•			osed of, onvertib		-	Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Ti	4. Transaction Code (Instr. 8)				6. Date Exercisable Expiration Date (Month/Day/Year)		te	e and 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio	ly [10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				С	ode	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	iii(s)			
Restricted Stock Units	(3)(4)	01/15/2019	01/15/201	19	A		22,131		(5)		(5)	Common Stock	22,131	\$0	22,131		D		
Restricted Stock	(4)	01/15/2019	01/15/201	19	M			7,823	(5)		(5)	Common Stock	7,823	\$0	14,466		D		

Explanation of Responses:

- $1. \ Acquired \ pursuant \ to \ vesting \ and \ release \ of \ shares \ pursuant \ to \ Restricted \ Stock \ Unit \ awards.$
- 2. Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
- 3. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.
- 4. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- 5. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

Remarks:

/s/Patrick R. ONeil 01/17/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.